Statements (27)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:chemical_compound
|
gptkbp:approvalYear |
1997
|
gptkbp:approvedBy |
gptkb:FDA
|
gptkbp:ATCCode |
L02BG04
|
gptkbp:bioavailability |
99%
|
gptkbp:CASNumber |
gptkb:53179-13-8
|
gptkbp:discoveredBy |
gptkb:Ciba-Geigy
|
gptkbp:hasInChIKey |
OBLPEUPLXAWFNA-UHFFFAOYSA-N
|
gptkbp:hasMolecularFormula |
C17H11N5
|
gptkbp:hasSMILES |
N#Cc1ccc(cc1)C=n2ncnc2c3ccc(cc3)C#N
|
gptkbp:hasUNII |
T6X3OCM1ZE
|
https://www.w3.org/2000/01/rdf-schema#label |
53179-13-8
|
gptkbp:IUPACName |
gptkb:4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile
|
gptkbp:legalStatus |
prescription only
|
gptkbp:meltingPoint |
184-185°C
|
gptkbp:molecularWeight |
285.31 g/mol
|
gptkbp:name |
gptkb:Letrozole
|
gptkbp:PubChem_CID |
3768
3902 CHEMBL716 DB01006 |
gptkbp:routeOfAdministration |
oral
|
gptkbp:solubility |
slightly soluble in water
|
gptkbp:usedAs |
aromatase inhibitor
|
gptkbp:usedFor |
treatment of breast cancer
|
gptkbp:bfsParent |
gptkb:Esbriet
|
gptkbp:bfsLayer |
7
|